Health News Releases

  • Today May 20
June 24, 2016 16:45
PENTAX Medical Appoints Dr. Hudson Garrett, Global Chief Clinical Officer
PENTAX Medical, a division of HOYA Corporation, announced the appointment of Dr. Hudson Garrett to the position of Global Chief Clinical Officer. In this executive role, Hudson Garrett is responsible
June 24, 2016 15:35
New SunTech Medical CT40 Vital Signs Device to Feature Masimo SET® Pulse Oximetry Technology
Masimo (NASDAQ: MASI) and SunTech Medical, a Halma (LSE:HLMA) company, jointly announced today the integration of Masimo SET® pulse oximetry technology into SunTech’s CT40, a next generation spot-chec
June 24, 2016 13:35
Q2 Solutions Receives 2016 Global Supplier Award from Eli Lilly and Company
Q2 Solutions, a global clinical trials laboratory services organization, today announced that the company has received the 2016 Lilly Global Supplier Award. Q2 Solutions was one of 12 companies to rec
June 24, 2016 10:10
BioLegend Enters License Agreement with Sanquin for Peptide-MHC Assay Technology
BioLegend announces that it has licensed from Sanquin Blood Supply Foundation a novel technology to study antigen-specific T cells. Through a collaborative effort, Sanquin’s Reagents Division and The
June 22, 2016 14:05
TB Alliance and Takeda Announce Advancement of Joint Program Investigating Promising Compounds for Novel TB Therapies Through Global Health Innovative Technology Fund
The Global Alliance for TB Drug Development (Headquarters: New York, USA, “TB Alliance”) and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; “Takeda”) announced that they have enter
June 22, 2016 13:30
Quintiles Unveils Solution Design Studio
Quintiles, the world’s largest provider of product development and integrated healthcare services, has opened its global Solution Design Studio where expert teams will collaborate to create technology
June 21, 2016 11:40
Mannatech: Leading the Revolution to End BMI as a Measure of Health
Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, is leading the health and weight loss industry by calling for the
June 20, 2016 16:00
Herbalife Partners with Global Football Star Cristiano Ronaldo to Launch New CR7 Drive Sports Drink
Herbalife, a global nutrition company, officially launched its new sports drink, CR7 Drive, at its annual Asia Pacific Extravaganza 2016, held in Seoul, Korea from June 17-19. Developed in collabor
June 17, 2016 14:45
Patient Safety Movement Applauds the Agency for Healthcare Research and Quality (AHRQ) & MedStar Health for Developing the CANDOR Toolkit
The Patient Safety Movement Foundation (PSMF) recommends that healthcare organizations around the world implement the Communication and Optimal Resolution (CANDOR) online toolkit published by the Agen
June 17, 2016 13:05
QUINTILES RECOGNIZED AS INDUSTRY LEADER FOR PHASE I, PHASE II/III AND PHASE IV SERVICES
Quintiles has been named the industry leader in Phase I, Phase II/III and Phase IV services, according to the Industry Standard Research’s (ISR) 2016 CRO Quality Benchmarking — Phases I, II/III and IV
June 16, 2016 14:00
Patient Safety Movement Announces Three New Patient Safety Challenges
The Patient Safety Movement Foundation announced three new patient safety challenges at its Midyear Planning Meeting co-convened with Inova. The 2016 Midyear Planning Meeting brought together over 100
June 15, 2016 15:55
Landmark Study Suggests Cranberries Can Decrease Use of Antibiotics
Today leading experts on infectious disease and urinary tract infections (UTIs) will gather in London to discuss the alarming state of antibiotic resistance and present findings from a landmark study
June 15, 2016 11:45
Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
New data showed Jardiance® (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39 percent versus placebo when added to standard of care in people with type 2 diabetes with es
June 13, 2016 11:50
New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance® (empagliflozin) compared with placebo when added to standard
June 13, 2016 10:50
New study results show Trajenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
Results from the MARLINA-T2DTM trial demonstrated that Trajenta® (linagliptin), which is marketed by Boehringer Ingelheim and Eli Lilly and Company, reduced blood sugar in adults with type 2 diabetes
June 10, 2016 18:00
Menarini Group and MSD Extends Global Partnership to the Asia-Pacific Region
Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini Asia-Pacific”) and MSD have embarked on a multi-year partnership for Menarini Asia-Pacific to assume the sales, marketing and distr
June 10, 2016 16:40
Masimo Announces Full Market Release of Next Generation SpHb® Spot Check Pronto®
Masimo (NASDAQ: MASI) announced today the full market release outside the U.S. of the Pronto® Pulse CO-Oximeter® with Next Generation SpHb® Spot Check technology. Next Generation Pronto features rainb
June 10, 2016 13:25
TAGRISSO (OSIMERTINIB) SHOWS CLINICAL ACTIVITY IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM LUNG CANCER
AstraZeneca today announced clinical and safety data for Tagrisso (osimertinib) in patients with leptomeningeal (LM) disease, a complication of epidermal growth factor receptor (EGFR) mutation-positiv
June 10, 2016 10:50
Lynparza (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
AstraZeneca today presented results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with Lynparza (olaparib) mai
June 09, 2016 18:15
DURVALUMAB MONOTHERAPY DEMONSTRATES EFFICACY IN UROTHELIAL BLADDER CANCER
AstraZeneca and its global biologics research and development arm, MedImmune, today announced efficacy and safety data for durvalumab, a selective programmed-death ligand-1 (PD-L1) antibody, in patien
June 09, 2016 16:00
Ascensia Diabetes Care Renews International Alliance with Medtronic
Today Ascensia Diabetes Care announced that it has renewed its global alliance with Medtronic plc to develop and market innovative diabetes management solutions for patients worldwide. As part of the
June 09, 2016 14:00
Market-leading TEVAR Device is First to Surpass 100,000 Devices Distributed Worldwide
W. L. Gore & Associates (Gore) today announced the GORE® TAG® Thoracic Device family has exceeded 100,000 devices distributed worldwide. Built on more than 18 years of success in both clinical studies
June 09, 2016 09:45
European Society of Anaesthesiology Partners with Patient Safety Movement to Lead the Movement to Zero Preventable Deaths in Europe
The European Society of Anaesthesiology (ESA) and the Patient Safety Movement Foundation announced today that on May 28, 2016 at the annual congress Euroanaesthesia 2016 in London, the ESA made a publ
June 09, 2016 09:15
Samsung Bioepis Announces New Data on Three Anti-TNF-α Biosimilar Molecules at the Annual European Congress on Rheumatology (EULAR 2016)
Samsung Bioepis Co., Ltd. today announced new clinical data on its anti-TNF-α portfolio of Benepali® (etanercept), Flixabi® (infliximab) and SB5 (adalimumab) investigational biosimilar candidate. The
June 08, 2016 18:00
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane® Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE® (paclitaxel
25 per page50 per page75 per page100 per page